Insilico Medicine Announces US$888M Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates January 4, 2026
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly January 4, 2026
BioAtla and GATC Health Announce a $40M SPV Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ OPSCC January 4, 2026
AbbVie secured global rights outside China to ZG006 (alveltamig) developed by Suzhou Zelgen Biopharmaceuticals January 4, 2026
Phase III Stage of the Ongoing Ph 2/3 Trial of Surufatinib – Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma Initiated January 4, 2026
Data Reported from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer January 4, 2026
IND application submitted to FDA for ALA-101 allogeneic CAR-iNKT cell therapy targeting CD19-positive NHL and leukemias January 4, 2026
Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) + Pembrolizumab for 1L PD-L1-Positive NSCLC January 4, 2026
NMPA approves TABOSUN + TYVYT combo for the neoadjuvant treatment of patients with stage IIB-III resectable MSI-H/dMMR colon cancer January 4, 2026
